Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 37 | ECE2015 | Next issue

17th European Congress of Endocrinology

Guided Posters


ea0037gp.19.01 | Pituitary–Acromegaly | ECE2015

Coagulation parameters and platelet function analysis in patients with acromegaly

Yasar Hamiyet Yilmaz , Demirpence Mustafa , Colak Ayfer , Ceyhan Banu Ozturk , Temel Yusuf , Simsek Nese , Karademirci Ismail , Bozkurt Umit

Objective: Acromegaly is associated with increased cardiovascular morbidity and mortality. But the data about the evaluation of coagulation and fibrinolysis in acromegalic patients is very limited and to our knowledge, platelet function analysis has never been investigated. So we aimed to investigate the levels of protein C, protein S, fibrinogen, antithrombin 3, and platelet function analysis in patients with acromegaly.Methods: Thirty-nine patients wit...

ea0037gp.19.02 | Pituitary–Acromegaly | ECE2015

Assessment of bone quality, measured by trabecular bone score, in acromegaly

Malchiodi Elena , Sala Elisa , Verrua Elisa , Cairoli Elisa , Carosi Giulia , Ferrante Emanuele , Filopanti Marcello , Ulivieri Fabio Massimo , Eller-Vainicher Cristina , Chiodini Iacopo , Mantovani Giovanna , Spada Anna

Introduction: Acromegaly is characterised by chronic exposure to high GH and IGF1 levels that leads to increased bone turnover. Regardless of BMD value, acromegalic patients seem to have an increased vertebral fracture risk probably due to a reduction of bone quality. Trabecular bone score (TBS) is a new index used for assessing bone microarchitecture. In this study TBS was used for the first time to analyze bone quality in acromegaly.Methods: 16 new acr...

ea0037gp.19.03 | Pituitary–Acromegaly | ECE2015

Perceived quality of life in acromegaly: results from a tertiary UK centre

Kyriakakis Nikolaos , Lynch Julie , Gilbey Stephen G , Webb Susan M , Murray Robert D

Introduction: Patients with acromegaly are frequently left with long-term adverse sequelae. When compared with individuals with other pituitary adenomas, patients with acromegaly demonstrate greater impairment in their quality of life (QoL).Methods: The disease-specific questionnaire, AcroQoL, and the generic psychological general well-being schedule (PGWBS) were used to evaluate QoL in an acromegaly patient cohort. Longitudinal data were also collected ...

ea0037gp.19.04 | Pituitary–Acromegaly | ECE2015

Molecular and pathological determinants of somatostatin analogue resistance: somatotropinomas in AIP mutated and X-LAG syndrome patients

Lee Misu , Daly Adrian , Rostomyan Liliya , Pellegata Natalia , Beckers Albert

Poor hormonal and tumour responses to somatostatin analogues (SSA) in acromegaly can occur although the aetiology is often unclear. Two genetic syndromes are associated with relative SSA resistance: acromegaly due to AIP mutations (AIPmut) and the newly described X-linked acrogigantism (X-LAG) syndrome due to chromosome Xq26.3 microduplications. We studied whether SSA resistance in these conditions was related to somatostatin receptor (SSTR) levels in tumour tissues. We studie...

ea0037gp.19.05 | Pituitary–Acromegaly | ECE2015

Clinical and biochemical outcomes during pregnancy in patients with acromegaly

O'Shea Triona , Guptha Saket , Melvin Audrey , McGurran Karen , Casey Ruth , O'Halloran Donal , Gibney James , Thompson Christopher , Sherlock Mark

Acromegaly is a rare condition resulting from excess secretion of GH and IGF1. Acromegaly is frequently associated with subfertility. As such there is little data on the course of the disease during pregnancy, and of the effects of the disease and its treatments on the foetus.Objective: We describe known pregnancies in women with acromegaly within the Republic of Ireland over a 15-year period.Methods: We collected clinical, biochem...

ea0037gp.19.06 | Pituitary–Acromegaly | ECE2015

Criteria for disease control in acromegaly under SSA treatment: mean GH profile or GH random?

Prencipe Nunzia , Bona Chiara , Karamouzis Joannis , Berton Alessandro Maria , Di Giacomo Stellina Valentina , Guaraldi Federica , Ghigo Ezio , Grottoli Silvia

Acromegaly is due to increased GH secretion usually sustained by a GH-secreting pituitary adenoma. Somatostatin analogues (SSA) can control GH hypersecretion in 60% of patients and tumor volume in 30%. The disease control is, in turn, associated with lower mortality and therefore to verify the optimal control of the disease activity is of critical importance to adapt the dose and the choice of alternative treatment. The criteria for optimized disease control had been assumed a...

ea0037gp.19.07 | Pituitary–Acromegaly | ECE2015

Patient experience of living with acromegaly in the UK

Brooke Antonia , Lyttle Jacqui , Goss Lynne , Pobereskin Louis , South West Peninsula Endocrinology Network

61 patients (104 invited participants), within 10 years of active treatment for acromegaly, from five hospitals in the South West Peninsula (UK) (one neurosurgical centre) were interviewed to explore the experience of living with acromegaly, access to information, support and their ability to make decisions about their care. Semi-structured interviews by an independent consultant (60–120 min each) included 34 males and 27 females; 25–85 years old; 52 (85%) patients h...

ea0037gp.19.08 | Pituitary–Acromegaly | ECE2015

Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly

Auriemma Renata S , Grasso Ludovica F S , Galdiero Mariano , Pivonello Claudia , Salzano Ciro , Negri Mariarosaria , Angelis Cristina de , Colao Annamaria , Pivonello Rosario

Somatostatin analogues (SA) are known to revert acromegalic cardiomyopathy mainly in young patients with short disease duration, whereas pegvisomant (PEG) reportedly improves cardiac structure and performance in patients resistant to SA. To date, no data are available on the effects of long-term SA+PEG on cardiovascular complications. The current study aimed at investigating the effects of long-term SA+PEG on cardiac structure and performance in acromegaly. Thirty-six acromega...

ea0037gp.19.09 | Pituitary–Acromegaly | ECE2015

Management of pasireotide-induced hyperglycaemia with proactive monitoring and early intervention: key learnings from the phase III, 24-week PAOLA study

Gadelha Monica R , Brue Thierry , Fleseriu Maria , Shimon Ilan , Resendiz Karina Hermosillo , Kandra Albert , Pedroncelli Alberto M , Colao AnnaMaria

Introduction: In PAOLA study, pasireotide showed superior efficacy over continued treatment with octreotide/lanreotide in patients with inadequately-controlled acromegaly; 64% of patients receiving pasireotide long-acting release (LAR) reported hyperglycaemia-related adverse events. Pasireotide has been shown to inhibit insulin secretion. The aim of this exploratory analysis was to investigate the effect of timing of antidiabetic medication (ADM) intervention on the fasting pl...

ea0037gp.19.10 | Pituitary–Acromegaly | ECE2015

A phase 2 study of antisense oligonucleotide therapy directed at the GH receptor demonstrates lowering of serum IGF1 in patients with acromegaly.

Trainer Peter , Newell-Price John , Ayuk John , Aylwin Simon , Rees Aled , Drake Will , Chanson Philippe , Brue Thierry , Webb Susan , Fajardo Carmen , Aller Javier , McCormack Ann , Torpy David , Tachas George , Atley Lynne , Bidlingmaier Martin

ATL1103 is a second generation antisense oligomer directed at the GH receptor. It is a 20mer with a phosphorothioate backbone and 2′-O-methoxyethyl modifications of the five nucleotides at either end intended to increase its plasma half-life and affinity for the target RNA to allow post-hybridization RNaseH degradation. We report a phase 2 randomised, open-label, parallel group study of subcutaneously administered ATL1103 in patients with active acromegaly. Appr...